Healthcare Industry News: shingles
News Release - February 9, 2006
David Peralta Joins NanoBio(R) as Chief Financial OfficerANN ARBOR, Mich., Feb. 9 (HSMN NewsFeed) -- NanoBio Corporation today announced the appointment of David Peralta to the position of vice president and chief financial officer. Peralta, a seasoned public- and private-company finance executive, brings 15+ years of financial and business management experience to NanoBio.
"We are delighted to add an executive of Dave's caliber to the NanoBio management team," said NanoBio chief executive officer Michael Nestor. "His arrival coincides with a very exciting period for NanoBio. We will certainly benefit from his vast experience as we seek to develop and commercialize our robust product pipeline of topical antimicrobial products, and pursue new opportunities for value creation in the future."
Mr. Peralta most recently served as vice president and chief financial officer for Arbortext, Inc., a venture-backed enterprise software company. While at Arbortext, Peralta played a key role in transforming the company to a fast-growing software business, which ultimately led to Arbortext being acquired in 2005 for $190 million in cash, a multiple of six times the company's prior-year revenue. Before joining Arbortext, Peralta served for six years as the chief financial officer of Mechanical Dynamics, Inc., a publicly-held engineering software company. Mr. Peralta directed all finance and investor relations activities at Mechanical Dynamics during the company's initial public offering in 1996, and up through the sale of the company in 2002.
"I am excited to be joining NanoBio," said Mr. Peralta. "The company's combination of a proven leadership team, validated technology, deep pipeline and tremendous growth prospects makes for a very compelling opportunity."
Peralta holds a Bachelor's degree in business administration from the University of Michigan, and is a certified public accountant.
NanoBio Corporation is a biopharmaceutical company developing and commercializing therapies based on proprietary nanoemulsion technology. This technology was developed at the University of Michigan Medical School. NanoBio, a privately held corporation, is the exclusive global licensee of this technology.
NanoBio has rapidly advanced its initial product for herpes labialis, NB- 001, through Phase II clinical trials, where it demonstrated efficacy and safety in over 300 patients in a Phase II, US-based clinical trial. NanoBio is also poised to initiate clinical trials in Europe in mid-2006 for its second product, NB-002, for onychomycosis.
Other products in the NanoBio product development pipeline include treatments for genital herpes, herpes zoster (shingles) and a broad-spectrum vaginitis treatment. Pre-clinical activity on nanoemulsion-based vaccines has been funded by the Gates Foundation and is also progressing. NanoBio believes that its proposed products could have important therapeutic, safety and cost advantages over currently available treatments.
Statements about NanoBio Corporation's future expectations, including proposed product development and regulatory plans, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. NanoBio intends that such forward-looking statements be subject to the safe harbors created thereby. NanoBio is not responsible for events not updated after the date on this press release.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.